Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial
详细信息 查看全文
- 作者：Yoko Ohtsukaa ; ohtsuka@okayama-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Harumi Yoshinagaa ; Yukiyoshi Shirasakab ; Rumiko Takayamac ; Hiroki Takanod ; Kuniaki Iyodae ; 1
- 关键词：Rufinamide ; Lennox&ndash ; Gastaut syndrome ; Long-term administration ; Safety ; Seizure outcome
- 刊名：Epilepsy Research
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：121
- 期：Complete
- 页码：1-7
- 全文大小：751 K
文摘
- •
Long-term adjunctive rufinamide therapy was beneficial for Lennox–Gastaut syndrome.
- •
Reduction of seizure frequency was maintained to 52 weeks in the extension study.
- •
Of 54 patients, 38 had rufinamide-related adverse events, mainly mild and moderate.
- •
Exacerbation of seizures and poor appetite/weight loss require attention.